Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients.
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety
of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal
cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
China Medical University, China
Collaborators:
Anshan Tumor Hospital Benxi Cental Hospital The First Affiliated Hospital of Dalian Medical University The People's Hospital of Liaoning Province The Second Affiliated Hospital of Dalian Medical University